Both isobaric and hyperbaric bupivacaine have been used for spinal anaesthesia for elective caesarean section, but it is not clear if one is better than the other. The primary objective of this systematic review was to determine the effectiveness and safety of hyperbaric bupivacaine compared with isobaric bupivacaine administered during spinal anaesthesia for elective caesarean section. We included 10 studies with 614 subjects in the analysis. There was no evidence of differences either in the risk of conversion to general anaesthesia, with a relative risk (95%CI) of 0.33 (0.09-1.17) (very low quality of evidence), or in the need for supplemental analgesia, the relative risk (95%CI) being 0.61 (0.26-1.41) (very low quality of evidence). There was also no evidence of a difference in the use of ephedrine, the amount of ephedrine used, nausea and vomiting, or headache. Hyperbaric bupivacaine took less time to reach a sensory block height of T4, with a mean difference (95%CI) of À1.06 min (À1.80 to À0.31). Due to the rarity of some outcomes, dose variability, use of adjuvant drugs and spinal technique used, future clinical trials should look into using adequate sample size to investigate the primary outcome of the need for supplemental analgesia. https://doi.org/10.1002/14651858.cd005143.pub3 (see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the CDSR should be consulted for the most recent version of the review.
Introduction
Caesarean section rates are high in many parts of the world; the incidence is reported to be 27.3% in Asia [1] , 15% in Thailand, 36% in Korea and 48% in Sweden [2] [3] [4] . For elective caesarean section, neuraxial anaesthesia, commonly spinal anaesthesia, is generally preferred to general anaesthesia; in some tertiary centres, neuraxial anaesthesia may be used in as many as 96% of caesarean sections [5] .
Bupivacaine is the most commonly-used local anaesthetic in spinal anaesthesia for caesarean section [6] . It is a long-acting local anaesthetic and available in two forms: an isobaric form and a denser hyperbaric form. Hyperbaric bupivacaine is produced by the addition of glucose (80 mg.ml
À1
) to isobaric ('plain') bupivacaine. The difference in density between the two forms is thought to affect the diffusion pattern and distribution after injection into the intrathecal space. Both forms have been widely used in spinal anaesthesia for caesarean section [7] .
The level of sensory blockade achieved after spinal injection is unpredictable. Physiological changes in pregnancy decreases local anaesthetic requirements and may increase the unpredictable extension of sensory block. Baricity of local anaesthetics could also be an important determinant of the distribution of anaesthetic in the intrathecal space, and hence the level of anaesthetic block. Several trials have compared hyperbaric bupivacaine and isobaric bupivacaine in spinal anaesthesia. Hyperbaric bupivacaine might appear to be associated with more predictable sensory blockade than isobaric bupivacaine. The two forms of bupivacaine also appear to differ in their motor blockade and duration of action. However, no study could conclusively show one to be better than the other [8, 9] .
We therefore aimed to perform a Cochrane systematic review to determine the effectiveness and safety of hyperbaric bupivacaine compared with isobaric bupivacaine for spinal anaesthesia in women undergoing elective caesarean section. The updated Cochrane version was published in 2016 [10] .
Methods
We searched CENTRAL, MEDLINE and Embase for material published between January 2011 and March 2016. We also searched the Cochrane Pregnancy and Childbirth Group Trials Register with the highly sensitive search strategy (HSSS) found in the Cochrane Handbook for Systematic Reviews of Interventions [11] . The Cochrane Pregnancy and Childbirth Group's Information Specialist searched the register for each review using these codes rather than keywords. There was no language restriction. In addition, we searched the three major anaesthesia conference abstracts, namely the Australian and New Zealand College of Anaesthetists' meeting, the American Society of Anesthesiologists' meeting and the European Society of Anaesthesiology meeting from 1990 to 2015. We identified no additional abstracts.
We included all randomised, controlled trials (RCT) involving healthy women undergoing spinal anaesthesia for elective caesarean section that compared the use of hyperbaric bupivacaine with isobaric bupivacaine. We included studies that used anaesthetic combinations containing spinal opioids (e.g. fentanyl, morphine) and those using the combined spinalepidural technique. The initial injection in this technique is a spinal anaesthetic and can thus be included in the analysis. We excluded studies using the sequential combined spinal-epidural technique, the use of other types of local anaesthetics concomitantly or use of other forms of anaesthesia for caesarean section. Any study that used cross-over or cluster-randomised designs was also excluded.
Our primary outcomes were: conversion to general anaesthesia, and inadequate pain control requiring the use of supplemental analgesics. The secondary outcomes were: the use of ephedrine; the incidence of nausea and vomiting; the incidence of headache within seven days of spinal anaesthesia; the time taken for the sensory block to reach the fourth thoracic dermatome; the amount of ephedrine used (mg per patient); and the occurrence of high sensory block (above the eighth cervical dermatome).
Three authors (WL, BS, FJS) independently extracted data from the included studies on a standardised data collection form and a fourth author (AS) resolved disagreements. We extracted information pertaining to the study design, method of randomisation, use of allocation concealment, reporting of the study setting and patients, inclusion and exclusion criteria, sample size, interventions and outcomes.
The quality of all trials was assessed for major potential sources of bias (random sequence generation; allocation concealment; blinding of patients and personnel; blinding of outcome assessment; the completeness of outcome data; and methods of reporting). We graded each of the above dimensions of trial quality as low risk, high risk or unclear risk of bias. We resolved any disagreements by consensus among the review authors. We reported risk ratios (RR) for binary outcomes, and mean differences (MD) for continuous outcomes. We evaluated clinical heterogeneity by qualitatively appraising the differences in study characteristics such as patients, interventions, outcomes assessed and study methodology. We agreed to pool data if studies were clinically similar. We informally evaluated and investigated the degree of statistical heterogeneity by visual inspection of forest plots, and more formally by the I 2 statistic [10] . We refrained from quantitative synthesis if a high degree of statistical heterogeneity existed, that is, I 2 above 75% [11] .
We checked the methodology sections and study protocols of the primary studies where available to assess the reporting biases. We used the randomeffects model where clinical heterogeneity could not be explained but statistical heterogeneity remained below the cut-off used for 'high' heterogeneity. Otherwise, we used fixed-effect estimates if it was deemed appropriate on both clinical and statistical grounds. We did not anticipate any sub-group analysis as there were only 10 included studies and not all of the included studies provided information for all the outcomes. The patient characteristics were also homogeneous, being restricted to pregnant women requiring elective caesarean section. We also graded the quality of evidence for each outcome using the GRADE approach, taking into account within-study risk of bias, inconsistency (heterogeneity), imprecision and indirectness [12] .
In addition, for this version of the review, at the request of the journal's reviewers, two authors (NH, RS) conducted trial sequential analyses. These were performed for primary outcomes using TSA version 0.9.5.5 beta (Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark) to explore whether cumulative data were adequately powered to evaluate outcomes [13] [14] [15] . The required information size and the O'Brien-Fleming adjacent trial sequential alpha spending monitoring boundaries were calculated based on a two-sided 5% risk of a type I error, 20% risk of a type II error (power of 80%), risk reduction based on pooled analysis, the weighted incidence of events in the control group and heterogeneity. Power of the primary outcomes was interpreted if significance was reached with either a minimal sample size or crossing trial sequential alpha spending monitoring boundary.
We also conducted a sensitivity analysis [16] to evaluate the effect of the method of analysis on the results where events were infrequent. As the data from this review could not fit into a single methodology satisfactorily, we used the Peto, Mantel-Haenszel and inverse variance methods to assess the robustness of the results.
Results
Searching, screening and inclusion are detailed in Fig. 1 . We included nine articles covering 10 studies reporting results from 614 patients. One study randomly allocated the patients into four groups [17] . Two out of those four groups received morphine, with one receiving isobaric and the other hyperbaric bupivacaine. The remaining two groups received fentanyl, with one receiving isobaric and the other hyperbaric bupivacaine. We treated these two sets as separate independent trials, since there was no double counting or need to adjust for correlation [17] . All 10 studies enrolled women at term and did not include women with complicated pregnancies (Table 1) . Four studies used the combined spinal-epidural technique with intrathecal injection [8, 9, 17] , whereas the remaining six studies used the spinal anaesthesia technique [18] [19] [20] [21] [22] [23] . The trials reported our two primary outcome measures, namely: the number of patients requiring conversion to general anaesthesia (10 studies), and the number of patients requiring supplemental analgesia (nine studies).
Among 14 excluded articles, two articles were excluded due to a lack of detailed information. The remaining 12 articles did not fulfil our inclusion criteria and were excluded for the following reasons: three out of the 12 excluded studies used hypobaric bupivacaine group [24] [25] [26] ; one used mepivacaine [27] ; two studies used tetracaine instead of bupivacaine [28, 29] ; three studies used combined spinal-epidural technique with the addition of local anaesthetics into epidural space [30] [31] [32] (although we only extracted data from the patients who had spinal anaesthesia without epidural injection); one study used differing concentration of isobaric and hyperbaric bupivacaine [33] ; whereas two studied employed sequential administration of isobaric and hyperbaric bupivacaine [34, 35] . Further details are given in the full Cochrane version [10] .
Only three studies described the method of randomisation [9, 19, 20] and one described the method of allocation concealment [20] . Five studies reported that randomisation resulted in intervention groups that were balanced at baseline [8, 18, 20, 22, 23] . All 10 studies were described as double blinded, but exactly which parties were blinded was not explicitly stated. We deduced that the patients were all blinded, due to the nature of the study as the spinal injections were done at the patient's lower back. The attending anaesthetists, who were also outcome assessors, were blinded to the group assignment in six of the studies [8, 9, 18, 20, 23] . A blinded assessor was involved in the study of Richardson et al. [21] , since the attending anaesthetists prepared the injections and followed the study protocol. The adequacy of blinding was not described in the study of Javed et al. [19] .
The amount of ephedrine administered was at the discretion of the attending anaesthetist. We judged the 10 studies as being at low risk of performance bias and detection bias [8, 9, [17] [18] [19] [20] [21] [22] [23] . Patients, who were blinded, were the outcome assessors for nausea and headache. All 10 studies had a low risk of attrition bias, as all outcome data (recruitment and attrition data) had been reported with no missing data. Nine studies reported all pre-specified outcomes. The details of methodological quality can be found in full Cochrane version [10] . All 10 studies (614 patients) reported the need for conversion to general anaesthesia; the chance of conversion to general anaesthesia with hyperbaric and isobaric bupivacaine were similar, with a risk ratio (95% CI) of 0.33 (0.09-1.17); I 2 = 22% (Fig. 2) . Seven out of the 10 studies reported no conversions in either treatment group [8, 9, 17, [20] [21] [22] . We downgraded the quality of the evidence for this outcome to 'very low' due to the uncertainty about the adequacy of the randomisation methods used and the imprecision of the results incorporating no events. Trial sequential analysis for this outcome indicated statistical significance in favour of hyperbaric bupivacaine (Fig 3) , as the cumulative Z-curve crossed the trial sequential monitoring boundary and did not enter the futility area. These findings indicated conclusive evidence, hence further trials may not be needed. Nine studies (554 patients) reported the need for supplemental analgesics [8, 9, [17] [18] [19] [20] [21] [22] [23] (Fig. 4) . Four studies [17, 20, 23] had no need for supplemental anaesthesia in either arm and the rest had a very low number of events. In most studies no more than one event was observed. The small number of events resulted in wide CIs, with the overall pooled result (RR (95%CI) 0.61 (0.26-1.41; I 2 = 0%, Fig. 4) showing that patients were unlikely to require supplemental analgesia. We categorised the quality of the evidence as 'very low' due to uncertainty about the adequacy of the randomisation methods used and the imprecision of the results incorporating no events. Trial sequential analysis for this outcome indicated no statistical significance in favour of hyperbaric, since the Z-curve crossed the trial sequential monitoring boundary. The required information size would be 3132 randomised participants and hence the accumulated evidence in our included studies is insufficient to make these findings conclusive (Fig. 5) .
With regard to the first of our secondary outcomes, four studies (256 patients) reported the use of ephedrine [8, 9, 19, 21] . One study with 97 patients was statistically significantly in favour of hyperbaric bupivacaine for reducing the need for ephedrine [8] . There was moderate heterogeneity (I 2 = 68%) so we used a random-effects model to account for unexplained variation among the studies. Overall, the requirement for ephedrine was similar, with a risk ratio (95%CI) of 0.89 (0.57-1.38). Different criteria were used in judging the need for ephedrine in these studies. Javed et al. [19] administered ephedrine when the systolic blood pressure fell more than 20% from the baseline value; Richardson et al. [21] left the need for ephedrine to the discretion of the attending anaesthetist; Sarvela et al. [9] administered ephedrine when the systolic blood pressure dropped below 95 mm Hg or decreased more than 20% from the baseline value; Vercauteren et al. [8] administered ephedrine when systolic blood pressure dropped below 100 mmHg or decreased more than 25% from the baseline value. In addition, the authors used a small dose of bupivacaine with the combined spinal-epidural technique, possibly leading to less use of ephedrine in both the hyperbaric and isobaric Figure 2 Forest plot of meta-analysis of the outcome 'conversion to general anaesthesia'. M-H, Mantel-Haentzel. bupivacaine groups. We categorised the quality of evidence for this outcome as 'very low' due to uncertainty about the adequacy of the randomisation methods used and the imprecision of the results incorporating no events.
Seven studies (433 patients) reported the occurrence of nausea and vomiting [8, 9, 17, [21] [22] [23] . Of these, one study was statistically significantly in favour of hyperbaric bupivacaine [8] and one study was statistically significantly in favour of isobaric bupivacaine in decreasing the incidence of nausea and vomiting [23] . We used the random-effects model to pool the data from these five studies. The pooled result showed no evidence of a difference, RR (95%CI) 0.99 (0.57-1.72). There was moderate heterogeneity (I 2 = 51%). We performed a sensitivity analysis to explore the underlying cause of the heterogeneity, but could find no apparent reason to account for it, although differing definitions of nausea and vomiting could not be discounted.
Sensitivity analysis did not change the conclusion. We categorised the quality of the evidence as 'low' due to uncertainty about the adequacy of the randomisation methods used. Three studies (234 patients) reported the occurrence of headache [8, 22, 23] . The pooled results were based on two studies [22, 23] with 137 patients. There was no increased risk of headache between the two groups (OR (95%CI) 1.82 (0.47-6.99); I 2 = 0%). We categorised the quality of the evidence as 'low' due to uncertainty about the adequacy of the randomisation methods used and the imprecision of the results incorporating no events. Two studies (128 patients) reported the time taken for the sensory block to reach the T4 level [21, 23] . The time taken was considerably shorter for hyperbaric bupivacaine, MD (95%CI) À1.06 (À1.80 to À0.31). There was no heterogeneity in the analysis. We categorised the quality of the evidence as 'moderate' due Figure 3 Trial sequential analysis of all trials for conversion to general anaesthesia.
to uncertainty about the adequacy of the randomisation methods used.
Six studies (386 patients) reported the amount of ephedrine used [8, 9, 17, 18, 20] . The six studies had a pooled MD (95%CI) of 0.23 (À1.65 to 2.12), showing no difference in the amount of ephedrine used. There was moderate heterogeneity (I 2 = 64%). We found no obvious methodological heterogeneity and hence we used the random-effects model to account for unexplained variation between studies. We categorised the p p Figure 4 Forest plot of meta-analysis of the outcome 'need for supplemental analgesics'. M-H, Mantel-Haentzel Figure 5 Trial sequential analysis of nine trials of the need for supplemental analgesics.
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quality of evidence as 'moderate' due to uncertainty about adequacy of the randomisation methods used.
Three studies (205 patients) reported the occurrence of undesirably high sensory block (higher than the C8 level) [8, 9, 22] . There was moderate statistical heterogeneity in the results (I 2 = 59%), but Vercauteren et al. [8] , which used low-dose bupivacaine with the combined spinal-epidural technique, differed directionally from the other two. Due to this clinical heterogeneity, we used the random-effects model to account for the additional variation. The pooled RR (95%CI) was 0.88 (0. 16-4.90 ). Finally, as data and results of the outcomes 'conversion to general anaesthesia', 'supplemental analgesia' and 'headache' only partially satisfied the criteria for using the Mantel-Haenszel or Peto methods (Table 2) , we repeated the analyses using the Mantel-Haenszel and inverse variance methods so that we could assess the impact of the analytical method on the results. This sensitivity analysis revealed that except for conversion to general anaesthesia, where the pooled result changed from significantly in favour of hyperbaric bupivacaine (Peto method) to no significant difference (Mantel-Haenszel and inverse variance methods), all other conclusions remained unchanged (no significant differences).
Discussion
This systematic review of 10 studies (614 patients) showed no evidence of a difference between hyperbaric and isobaric bupivacaine in the rates of conversion to general anaesthesia or the need for supplemental analgesia. There were only three studies [18, 19, 23] that contributed to the result of similar conversion to general anaesthesia and five studies [9, 18, [21] [22] [23] contributed to the result of similar requirement for supplemental analgesia. Two studies [21, 23] contributed to the result of more rapid onset of sensory block at the T4 level with hyperbaric bupivacaine. All other analyses showed no differences. In addition, the relatively small sample populations within the included studies may suggest that the results should be treated with caution, as future larger studies may modify these findings.
Conversion to general anaesthesia was a rare event in the 10 studies. Most studies did not report any conversions to general anaesthesia [8, 9, 17, [20] [21] [22] ; das Neves et al. and Javed et al. [18, 19] did not show any significant differences, and the evidence for the superiority of hyperbaric bupivacaine comes primarily (78% weight) from one study [23] . The criterion used in Vichitvejpaisal et al. [23] for conversion to general anaesthesia was when the analgesic level was deemed inadequate, but no further details were given. Caution should be exercised in interpreting the clinical significance of this finding.
The pooled estimate for use of supplemental analgesia was also dominated by a single study [8] (61% weight), as this study reported more events and was significantly larger than the other studies. The larger number of events might be attributable to the use of a smaller spinal dose in the patients scheduled for combined spinal-epidural anaesthesia, leading to a higher event rate for supplemental analgesia.
The use of ephedrine was lowest in Vercauteren et al. [8] , as the dose of bupivacaine was only 6.6 mg using the combined spinal-epidural technique, compared with a higher ephedrine consumption by das Neves et al. (12.5 mg bupivacaine) and Sarvela 1999 (9 mg bupivacaine) using spinal anaesthesia [9, 18] . For caesarean section, an anaesthesia level of T4 has been widely considered as the standard to allow pain-free delivery of the infant. We therefore reviewed the mean time to onset of T4 blockade, which was only reported in two studies [21, 23] . Both studies used the loss of sensation to pinprick as the test for sensory level. We could not investigate the maximum sensory level achieved during intrathecal block or recession of sensory blockade, due to the different methods used to test sensory level. Vercauteren et al. [8] used ether swabs to test the height of block, whereas others used loss of sensation to pin-prick or cold.
There was unclear risk of bias for allocation concealment selection bias, as the methods were not reported in nine studies [8, 9, [17] [18] [19] [21] [22] [23] . In Richardson et al. [21] , the two groups were not balanced for prognostically important factors, for example, previous caesarean sections. Other than the study by Punshi and Afshan [20] , which had a high risk of reporting bias, there were low risks of performance bias, detection bias, attrition bias, reporting bias or other potential biases. Although it is impossible to blind the anaesthetist when regional techniques are employed [36] , there were other inconsistencies in blinding, variation in the dose of bupivacaine used and in the block technique deployed, variation in the degree of discretion over giving ephedrine permitted for the attending anaesthetist, and the small number of events (sometimes zero) for most of the dichotomous outcomes. Therefore, considering both the risk of bias and imprecision, we categorised the evidence as either 'very low' or 'low' for five out of the seven outcomes assessed using the GRADE methods.
In conclusion, there is no compelling evidence in favour of isobaric over hyperbaric bupivacaine, or vice versa, for spinal anaesthesia for caesarean section. Due to the suggestive evidence of faster onset to T4 sensory block, intrathecal hyperbaric bupivacaine may have some advantages. However, an adequately powered randomised controlled trial is required, in which the criteria for conversion to general anaesthesia and the need for supplemental analgesia should be defined objectively, applied uniformly and reported explicitly. Other clinically important outcomes, such as pain scores in the peri-operative period and time to walking, need to be evaluated in a standardised manner. All clinically relevant sideeffects should be evaluated. Reporting standards should adhere to the CONSORT guidelines with more details of randomisation, blinding and complete outcome data assessment.
